The abstract is read at the publisher; the summary is JClub's.
Retifanlimab plus carboplatin and paclitaxel improved progression-free survival in 308 treatment-naïve patients with unresectable or metastatic squamous cell carcinoma of the anal canal, HR 0.63.
- Why it matters: Patients with unresectable or metastatic SCAC need effective systemic options, and prior systemic therapies leave limited room for durable disease control.
- What they did: In POD1UM-303, 308 patients were randomized 1:1 to retifanlimab or placebo, each with carboplatin and paclitaxel, with PFS assessed by blinded independent central review.
- The result: Median PFS was 9.3 months versus 7.4 months, and interim overall survival was not statistically significant (HR 0.70), supporting a new combination option.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.